Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894331 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL5894336 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2MAOAMAOBALDH1A1MAPT | |
| SCHEMBL11108451 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2MAOAMAOBPDGFRBALDH1A1 | |
| SCHEMBL5873851 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2MAOAMAOBPDGFRBALDH1A1 | |
| SCHEMBL397664 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2PDGFRBALDH1A1MAPTNPSR1 | |
| SCHEMBL11892099 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2PDGFRBALDH1A1MAPTNPSR1 | |
| SCHEMBL397665 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2PDGFRBALDH1A1MAPTNPSR1 | |
| SCHEMBL4975317 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2MAOAMAOBPDGFRBALDH1A1 | |
| SCHEMBL10398762 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1MAPTNPSR1RET | |
| SCHEMBL10398764 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1MAPTNPSR1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | SMN1; SMN2 3527/4885MAOA 2011/4885MAOB 1993/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | SMN1; SMN2 4854/4885MAOA 2705/4885MAOB 2821/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | SMN1; SMN2 4631/4885MAOA 3420/4885MAOB 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.